AMA recognizes the following companies as the key players who are driving Arthritis Drug market, some of them are Novartis AG (Switzerland), Eli Lilly and Company (United States), Amgen Inc. (United States), Merck & Co., Inc. (United States), Bristol-Myers Squibb Company (United States), Pfizer Inc. (United States), Johnson & Johnson (United States), F. Hoffmann-La Roche Ltd (Switzerland), Bayer AG (Germany) and Sanofi S.A. (France).

An analyst from AdvanceMarketAnalytics team said: “One of the key factors which is trending the market is “Self-Awareness And Pro-Activeness To Seek Treatment”. Considering the revolutionary changes occurring in this market, there is a growing demand from the use of Arthritis Drug such as Synthetic DMARDs, Biological DMARDs, NSAIDs, Corticosteroids and Analgesics.

According to the report, some of the important driving forces behind the market growth are “Increasing prevalence in geriatric population especially women ”. The primary concern of any business is the reduction of the overall operating cost. The increased need for operating efficiency and meeting regulatory demands at the same time have become major challenges for the original Players, additional restraints impacting market are “High Cost Of Arthritis Drugs” which is continuously seeking attention of Industry Experts and Decision makers.

The study was conducted using primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market study and vendor landscape in addition to a SWOT analysis of the key Players.